Your browser doesn't support javascript.
loading
Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers.
Batalini, Felipe; Gulhan, Doga C; Mao, Victor; Tran, Antuan; Polak, Madeline; Xiong, Niya; Tayob, Nabihah; Tung, Nadine M; Winer, Eric P; Mayer, Erica L; Knappskog, Stian; Lønning, Per E; Matulonis, Ursula A; Konstantinopoulos, Panagiotis A; Solit, David B; Won, Helen; Eikesdal, Hans P; Park, Peter J; Wulf, Gerburg M.
Affiliation
  • Batalini F; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Gulhan DC; Beth Israel Deaconess Medical Center, Division of Medical Oncology and Cancer Research Institute, Boston, Massachusetts.
  • Mao V; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Tran A; Harvard Medical School, Department of Biomedical Informatics, Boston, Massachusetts.
  • Polak M; Harvard Medical School, Department of Biomedical Informatics, Boston, Massachusetts.
  • Xiong N; Harvard Medical School, Department of Biomedical Informatics, Boston, Massachusetts.
  • Tayob N; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Tung NM; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts.
  • Winer EP; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Mayer EL; Dana-Farber Cancer Institute, Department of Data Sciences, Boston, Massachusetts.
  • Knappskog S; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Lønning PE; Dana-Farber Cancer Institute, Department of Data Sciences, Boston, Massachusetts.
  • Matulonis UA; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Konstantinopoulos PA; Beth Israel Deaconess Medical Center, Division of Medical Oncology and Cancer Research Institute, Boston, Massachusetts.
  • Solit DB; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Won H; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts.
  • Eikesdal HP; Harvard Medical School, Department of Medicine, Boston, Massachusetts.
  • Park PJ; Dana-Farber Cancer Institute, Department of Medical Oncology, Boston, Massachusetts.
  • Wulf GM; University of Bergen, Department of Clinical Science, Bergen, Norway.
Clin Cancer Res ; 28(21): 4714-4723, 2022 11 01.
Article in En | MEDLINE | ID: mdl-36048535
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Triple Negative Breast Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Ovarian Neoplasms / Triple Negative Breast Neoplasms Type of study: Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Female / Humans Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2022 Document type: Article